Vertex’s Kaftrio+Ivacafor Receives EC’s Approval for the Treatment of Children aged 2 to 5yrs. with Cystic Fibrosis (CF)
Shots:
- Vertex Pharmaceutical receives EC’s approval to expand the label of Kaftrio + Ivacaftor for treating children aged 2 to 5 with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene
- The real-world data from the trial demonstrated the clinical benefit of Kaftrio in CF among young children across Europe, extended Kaftrio indication will soon be available to patients in Austria, Denmark, Ireland, Norway, Latvia, & Sweden
- Kaftrio in combination with ivacaftor is an oral medicine aimed at enhancing both the quantity and functionality of the CFTR protein on the cell surface
Ref: Vertex | Image: Vertex
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
